A Study of Ixekizumab in Participants With Active Psoriatic Arthritis
Launched by ELI LILLY AND COMPANY · Sep 25, 2012
Trial Information
Current as of July 21, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Presents with established diagnosis of active psoriatic arthritis for at least 6 months, and currently meets Classification for Psoriatic Arthritis (CASPAR) criteria
- • Active psoriatic arthritis (PsA) defined as the presence of at least 3 tender and at least 3 swollen joints
- • Presence of active psoriatic skin lesion or a personal history of plaque psoriasis (Ps)
- • Men must agree to use a reliable method of birth control or remain abstinent during the study
- • Women must agree to use reliable birth control or remain abstinent during the study and for at least 12 weeks after stopping treatment
- Exclusion Criteria:
- • Current or prior use of biologic agents for treatment of Ps or PsA
- • Inadequate response to greater than or equal to 4 conventional disease-modifying antirheumatic drugs (DMARDs)
- • Current use of more than one conventional DMARD
- • Evidence of active inflammatory arthritic syndromes or spondyloarthropathies other than PsA
- • Have participated in any study with interleukin 17 (IL-17) antagonists, including ixekizumab
- • Serious disorder or illness other than psoriatic arthritis
- • Serious infection within the last 3 months
- • Breastfeeding or nursing (lactating) women
About Eli Lilly And Company
Eli Lilly and Company is a global healthcare leader dedicated to creating innovative medicines that improve patient outcomes across a range of therapeutic areas, including diabetes, oncology, immunology, and neurodegenerative diseases. With a rich history of scientific research and a commitment to advancing healthcare, Lilly invests significantly in clinical trials to develop new treatments and enhance existing therapies. The company prioritizes patient safety and ethical standards in its clinical research, fostering collaboration with healthcare professionals and stakeholders to ensure the delivery of high-quality, evidence-based solutions that address unmet medical needs worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Liège, , Belgium
Monterrey, , Mexico
Moscow, , Russian Federation
Charlotte, North Carolina, United States
Dallas, Texas, United States
Ottawa, Ontario, Canada
Bordeaux, , France
Nantes, , France
Trumbull, Connecticut, United States
Indianapolis, Indiana, United States
Amsterdam, , Netherlands
Okayama, , Japan
Sabadell, , Spain
Pleven, , Bulgaria
Little Rock, Arkansas, United States
Atlanta, Georgia, United States
Gent, , Belgium
Genk, , Belgium
Barcelona, , Spain
Tampa, Florida, United States
London, , United Kingdom
Toulouse, , France
Toms River, New Jersey, United States
Santander, , Spain
Maastricht, , Netherlands
Mexico City, , Mexico
Saint Petersburg, , Russian Federation
Decatur, Georgia, United States
Spokane, Washington, United States
Wolverhampton, West Midlands, United Kingdom
Chihuahua, , Mexico
Bilbao, , Spain
Upland, California, United States
Orangeburg, South Carolina, United States
Huntsville, Alabama, United States
Marietta, Georgia, United States
Greensboro, North Carolina, United States
Majadahonda, , Spain
Birmingham, Alabama, United States
Zephyrhills, Florida, United States
Saint Louis, Missouri, United States
Seattle, Washington, United States
Plovdiv, , Bulgaria
Katowice, , Poland
Krakow, , Poland
Wroclaw, , Poland
Kharkiv, , Ukraine
Lutsk, , Ukraine
Duncansville, Pennsylvania, United States
Boca Raton, Florida, United States
Liverpool, , United Kingdom
Ivano Frankivsk, , Ukraine
Orleans, , France
Kennewick, Washington, United States
Guadalajara, , Mexico
Cumberland, Maryland, United States
Cambridge, Cambridgeshire, United Kingdom
Waterloo, Ontario, Canada
Cordoba, , Spain
Hagerstown, Maryland, United States
Osaka, , Japan
Wichita, Kansas, United States
Dayton, Ohio, United States
Durham, North Carolina, United States
Zlin, , Czechia
Orange Park, Florida, United States
Columbia, South Carolina, United States
Jackson, Tennessee, United States
Lviv, , Ukraine
Zaporizhzhia, , Ukraine
Brooklyn, New York, United States
Petrozavodsk, , Russian Federation
Donetsk, , Ukraine
Odesa, , Ukraine
Clarksburg, West Virginia, United States
Warsaw, , Poland
Voorhees, New Jersey, United States
Kazan, , Russian Federation
Sevilla, , Spain
Tuscaloosa, Alabama, United States
Cedar Rapids, Iowa, United States
Rochester, New York, United States
Houston, Texas, United States
Sliven, , Bulgaria
Sofia, , Bulgaria
Stara Zagora, , Bulgaria
Toronto, Ontario, Canada
Quebec, , Canada
Brno, , Czechia
Bruntal, , Czechia
Hlucin, , Czechia
Ostrava Trebovice, , Czechia
Prague, , Czechia
Tallinn, , Estonia
Fukuoka, , Japan
Hokkaido, , Japan
Tokyo, , Japan
San Luis Potosi, , Mexico
Almelo, , Netherlands
Nijmegen, , Netherlands
Rotterdam, , Netherlands
Sneek, , Netherlands
Bialystok, , Poland
Lublin, , Poland
Poznan, , Poland
Sroda Wielkopolska, , Poland
Barnaul, , Russian Federation
Ekaterinburg, , Russian Federation
Málaga, , Spain
Dnipropetrovsk, , Ukraine
Kyiv, , Ukraine
Vinnytsia, , Ukraine
Goodmayes, Essex, United Kingdom
Headington, Oxford, United Kingdom
Bradford, West Yorkshire, United Kingdom
Leeds, West Yorkshire, United Kingdom
Patients applied
Trial Officials
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director
Eli Lilly and Company
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials